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A B S T R A C T
Thrombomodulin (TM) is an endothelial cell membrane protein that plays essential roles in controlling vascular
haemostatic balance. The 4, 5, 6 EGF-like domain of TM (TM456) has cofactor activity for thrombin binding and
subsequently protein C activation. Therefore, recombinant TM456 is a promising anticoagulant candidate but has
a very short half-life. Ligation of poly (ethylene glycol) to a bioactive protein (PEGylation) is a practical choice to
improve stability, extend circulating life, and reduce immunogenicity of the protein. Site-specific PEGylation is
preferred as it could avoid the loss of protein activity resulting from nonspecific modification. We report herein
two site-specific PEGylation strategies, enzymatic ligation and copper-free click chemistry (CFCC), for rTM456
modification. Recombinant TM456 with a C-terminal LPETG tag (rTM456-LPETG) was expressed in Escherichia coli
for its end-point modification with NH2-diglycine-PEG5000-OMe via Sortase A-mediated ligation (SML).
Similarly, an azide functionality was easily introduced at the C-terminus of rTM456-LPETG via SML with NH2-
diglycine-PEG3-azide, which facilitates a site-specific PEGylation of rTM456 via CFCC. Both PEGylated rTM456
conjugates retained protein C activation activity as that of rTM456. Also, they were more stable than rTM456 in
Trypsin digestion assay. Further, both PEGylated rTM456 conjugates showed a concentration-dependent pro-
longation of thrombin clotting time (TCT) compared to non-modified protein, which confirms the effectiveness
of these two site-specific PEGylation schemes.
1. Introduction
Thrombomodulin (TM) is an endothelial cell membrane protein that
plays essential roles in controlling vascular haemostatic balance by
activating anticoagulant and anti-inflammatory proteins and simulta-
neously inactivating pro-coagulant and pro-inflammatory proteins
(Dittman and Majerus, 1990). TM serves as a receptor for thrombin and
directly inhibits its pro-coagulant activity (direct anticoagulant ac-
tivity). So far, various forms of TM have been cloned and recombinant
expressed for structural and functional study of TM (Wang et al., 2014).
Actually, various recombinant TMs show promising antithrombotic and
anti-inflammatory activity in vitro and in vivo (Ma et al., 2015). Parti-
cularly, recombinant human soluble TM (ART-123) has been approved
in Japan for DIC treatment (Itoh et al., 2016). However, a phase III trial
of ART-123 for DIC in USA was withdrawn in 2019 (van der Poll, 2019).
It is speculated that recombinant human soluble TM has many domains
that have different activities. The last three consecutive EGF-like
domains (E456) are responsible for the anticoagulant activity of TM
(Zushi et al., 1989). Specifically, the E56 domains of TM bind thrombin,
while promoting protein C binding to the E45 domains of TM, together
converting protein C to activated protein C (APC) (Fuentes-Prior et al.,
2000). Meanwhile, TM binding prevents the binding of thrombin to its
pro-coagulant substrates, such as fibrinogen and coagulation factors V
and VIII. Therefore, recombinant EGF-like domains 4, 5, 6 of TM
(TM456) is a promising anticoagulant candidate. However, its half-life is
very short (6–9min) in animal models (Suzuki et al., 1998).
Modification of protein can expand the protein's pharmacodynamic
and pharmacokinetic properties, such as functional capacity and sta-
bility (Pelegri-O'Day et al., 2014). Covalent conjugation of polyethylene
glycol (PEG) molecule to protein has been used successfully in ap-
proved protein drugs (Turecek et al., 2016). The key point for a prac-
tical protein modification is to carry out site-specific chemistry to avoid
upsetting the protein's activity due to random modification (Dozier and
Distefano, 2015; Nischan and Hackenberger, 2014). Bio-orthogonal
T
2. Materials and methods
2.1. Materials and reagents
All solvents, chemicals and reagents were purchased from com-
mercial sources and were used unless otherwise noted. pET39b vector,
pET28b vector and competent cells were purchased from EMD
Chemicals. Kanamycin sulfate and IPTG (Isopropyl-beta-D-thioga-
lactopyranoside) were purchased from Calbiochem. The mouse mono-
clonal antibody specific to human TM, rabbit monoclonal antibody
specific to Polyethylene glycol (PEG), goat anti-mouse IgG H&L (HRP)
and goat anti-rabbit IgM mu chain (HRP) were purchased from Abcam.
Human protein C, human thrombin and human antithrombin III were
obtained from Haematologic Technologies Inc. Chromogenic thrombin
substrate BIOHPEN CS-01(38) and bovine serum albumin (BSA) were
from Fisher Scientific. Heparin, Aprotinin and Trypsin were purchased
from Sigma. Pooled normal human plasma was from Innovative
Research. NH2-Gly-Gly-PEG3-azide and NH2-Gly-Gly-NH-PEG5000-OMe
were purchased from CarboSynUSA. DBCO-Cy5 and DBCO-mPEG5000-
OMe were purchased from Click Chemistry Tools.
2.2. Expression and purification of rTM456-LPETG
The recombinant TM contained the EGF domain 4–6 of human
thrombomodulin with a FLAG tag on N-terminal, a C-terminal LPETG
sequence and a His tag (rTM456) was expressed and purified as pre-
viously described with some modification (Jiang et al., 2012). The ex-
pression plasmid, pET39b-rTM456 was transformed into E. coli. B834
(DE3) cells for expression. The E. coli. B834 (DE3) cells were incubated
in LB medium with 35 μg/mL kanamycin at 37 °C, shaking at 150 rpm
until an OD600 of 0.8 was reached, and then IPTG was added to a final
concentration of 1mM to induce the overexpression of rTM456 by in-
cubation for 5 h at 37 °C. The bacteria were then centrifuged at 8000g
for 5min, and the cell pellets were collected and purified or stored in
−80 °C.
The bacteria pellets were resuspended in 10mL of ice-cold lysis
buffer (20mM Tris and 150mM NaCl, pH 8.0) with 1mM PMSF (phe-
nylmethanesulfonyl fluoride) and lysed by sonication. The extract was
collected by centrifugation at 20,000g for 15min, then loaded into
HisTrap FF column (GE Healthcare) charged with Ni2+ ions and eluted
with buffer (20mM Tris, 0.5M NaCl and 250mM imidazole, pH 8.0).
Pooled fractions containing rTM456-LPETG were collected and then
dialyzed by Amicon Ultra Centrifugal Filter (Millipore) with a cutoff
molecular weight of 10,000 Da to afford rTM456-LPETG. Sterilized
glycerol was added to the rTM456-LPETG solution to a final
Fig. 1. Domain structures of recombinant TM456 fragment and its end-point PEGylation strategy via SML and CFCC.
chemistry has been developed for selective and efficient modification of 
proteins (Willems et al., 2011). The most widely used approaches are 
azide-reactive Staudinger ligation (Cazalis et al., 2004) and click 
chemistry (Agard et al., 2006). These approaches benefit from the azide 
functionality since it is small, bears no overall charge and can be in-
troduced with relative ease to a wide variety of structures, often 
without disruption to biological behavior of proteins. On the other 
hand, enzymatic ligation has been explored for selective protein mod-
ification in native linkages as well (Wu and Guo, 2012). For example, 
Sortase A-mediated ligation (SML) has been utilized to site-specifically 
modify proteins (Tsukiji and Nagamune, 2009). Specifically, Sortase A 
(SrtA) recognizes the unique pentapeptide LPXTG, where X is variable, 
of the C-terminal domain of target proteins and transfers the carboxylic 
group of Thr to a substrate carrying an N-terminal glycine to afford the 
transpeptidation products. Therefore, SML could be used for direct 
PEGylation of protein containing LPXTG with glycine-functionalized 
PEG molecule (Popp et al., 2011).
In this report, we expressed a recombinant rTM456-LPETG with a 
FLAG fusion tag at the N-terminus and a His-tag at the C-terminus, in 
which the LPETG motif facilities end-point modification of rTM456 with 
diglycine chain-end functionalized PEG catalyzed by SrtA, which also 
has a His-tag at the C-terminus. The His-tag on both rTM456-LPETG and 
SrtA allows for an easy cleanup of the unreacted rTM456-LPETG and 
SrtA by nickel affinity column after the SML reaction. In our previous 
study, we expressed recombinant TM containing an azido-functiona-
lized methionine analog at the C-terminus (rTM456-Azide) for site-spe-
cific rTM456 modification (Zhang et al., 2013). However, the low ex-
pression yield of the rTM456-Azide with the unnatural amino acid limits 
its further functional investigation and practical application as well. 
Alternatively, rTM456 containing a LPETG pentapeptide at C-terminus 
was expressed in higher yield, through which diGly-PEG3-azide could 
be conjugated via SML to incorporate azide functionality into the C-
terminus of rTM456 (Jiang et al., 2012; Wang et al., 2016). This ap-
proach affords the higher overall yield for preparing recombinant 
TM456 with azide functionality at its C-terminus and thus facilitates a 
site-selective PEGylation of rTM456 with DBCO chain-end functiona-
lized PEG via Copper-free click chemistry (CFCC) (Fig. 1). Overall, both 
enzymatic and chemical modification aimed to add PEG to rTM456 at a 
specific site generated homogenous rTM456 conjugates. These site-spe-
cific modification strategies will lay the foundation for developing TM-
based antithrombotic agents with enhanced antithrombotic activity and 
pharmacokinetic properties.
and then incubated with a secondary antibody (goat anti-mouse IgG
HRP or goat anti-rabbit IgM HRP 1:5000) in 5% non-fat milk for 1 h at
room temperature. After washing with TBST (3×10min), protein
bands on the membrane were visualized using an enhanced chemilu-
minescence (ECL) solution (Thermo fisher).
2.7. Stability of rTM456-LPETG and PEGylated rTM456-LPETG conjugates
under proteolytic digestion by trypsin
Briefly, 10 μg of rTM456-LPETG, rTM456-PEG5000-OMe or rTM456-
PEG3-PEG5000-OMe, was incubated with 20 μg of Trypsin in the reaction
buffer (20mM Tris and 150mM NaCl, pH 8.0) at 37 °C for 0, 1, 2, 3, 4, 5
and 6 h, respectively. Then the reaction mixture was supplemented with
SDS-PAGE reducing sample buffer, heated to 100 °C for 10min, and
then electrophoresed on SDS-PAGE (15% acrylamide) gels. The amount
of undigested protein in a given lane was determined by Western blot
by anti-TM and anti-PEG antibodies, respectively. Image J software was
employed to calculate the band intensity of rTM456-LPETG, PEGylated
rTMs and their remains after Trypsin digestion in three independent
experiments.
2.8. Protein C activation activity assay of rTM456-LPETG and PEGylated
rTM456-LPETG conjugates with or without trypsin digestion
The cofactor activities of rTM456-LPETG, rTM456-PEG5000-OMe,
rTM456-PEG3-PEG5000-OMe and their Trypsin digestion products were
assessed by protein C activation assay as previously described with
some modification (Popp et al., 2011). Briefly, rTM456-LPETG and PE-
Gylated rTMs obtained from the above conjugation were added into
assay buffer (20mM Tris, 150mM NaCl, 5 mM CaCl2 and 0.1% BSA,
pH 8.0) containing 200 nM of human protein C (PC) to a final con-
centration of 50 nM, and the reaction volumes were adjusted to 100 μL.
The PC activation was initiated with the addition of human α-thrombin
to a final concentration of 10 nM. After incubation for 1 h at 37 °C while
shaking, the PC activation was terminated by addition of 30 μL human
antithrombin III (1 mg/mL) and 2 μL heparin (10 U/mL) for 10min at
37 °C while shaking. The activated PC was measured by incubation with
chromogenic thrombin substrate BIOHPEN CS-01(38) (0.5 mM) for
20min at 37 °C to determine its enzymatic activity. The UV absorbance
at 405 nm was measured.
For protein C activation assays, Trypsin digestion reaction of
rTM456-LPETG, rTM456-PEG5000-OMe and rTM456-PEG3-PEG5000-OMe
were stopped by adding 10 μg/mL of Aprotinin in the reaction buffer to
avoid the effect of Trypsin on protein C activation. All protein C acti-
vation assays were conducted as above with the presence of Aprotinin.
2.9. Thrombin clotting time (TCT) assay of PEGylated rTM456-LPETG
conjugates
rTM456-LPETG, rTM456-PEG5000-OMe and rTM456-PEG3-PEG5000-
OMe (0.002mg/mL, 0.004mg/mL and 0.005mg/mL) in normal human
plasma were prepared, and similar concentrations of NH2-Gly-Gly-NH-
PEG5000-OMe and DBCO-PEG5000-OMe were prepared as controls. The
clotting of each sample (100 μL) was triggered by adding 200 μL of
human thrombin (5 U/mL). The TCT was measured by BBL fibrometer
(Becton-Dickinson). The initial point was obtained with buffer (20mM
Tris and 150mM NaCl, pH 8.0) alone.
2.10. Statistical analysis
All data is presented as the means ± the standard error of the
mean. Differences between experimental groups were analyzed using
one-way ANOVA with an independent t-test. All reported p values were
two-tailed, and p values of< 0.05 were considered statistically (*,
p < 0.05; **, p < 0.01; ***, p < 0.001). Statistical analyses were
performed with SPSS 16.0 software.
concentration is 10% to keep rTM456-LPETG activity. After detection of 
the concentration of this rTM456-LPETG solution by Bradford method, 
the rTM456-LPETG was aliquoted and stored in −80 °C.
2.3. Expression and purification of soluble SrtA
SrtA with a C-terminal His tag was expressed and purified from E. 
coli BL21 as previously described (Tsukiji and Nagamune, 2009). 
Briefly, the E. coli BL21 transformed with the plasmid pET28b-SrtA 
were grown in LB medium to an OD600 of 0.8 at 37 °C, and protein 
expression was induced by the addition of IPTG to a final concentration 
of 1 mM for 5 h. Then the bacteria cells were harvested by centrifuga-
tion and resuspended in 10 mL of ice-cold lysis buffer (20 mM Tris and 
150 mM NaCl, pH 8.0) with 1 mM PMSF, and lysed by sonication. The 
extract was centrifuged at 20,000g for 15 min, and supernatant was 
applied onto HisTrap FF column charged with Ni2+ ions and eluted 
with buffer (20 mM Tris, 0.5 M NaCl and 250 mM imidazole, pH 8.0). 
The pooled fractions containing SrtA were collected and dialyzed, then 
kept in 10% glycerol and stored in −80 °C until use.
2.4. C-terminal covalent PEGylation of rTM456-LPETG via Sortase A-
mediated ligation (SML)
rTM456-LPETG (14 μM) was mixed with SrtA (2 μM) and NH2-Gly-
Gly-NH-PEG5000-OMe (133 μM) in reaction buffer (20 mM Tris and 
150 mM NaCl, pH 8.0). The reaction mixture was then incubated at 
37 °C for 3 h to obtain the C-terminal PEGylated rTM456 (rTM456-
PEG5000-OMe). The obtained rTM456-PEG5000-OMe was purified from 
the remaining reaction mixture by collecting the pass-through fraction 
of His SpinTrap column (GE Healthcare). Excess NH2-Gly-Gly-NH-
PEG5000-OMe was then removed by Amicon Ultra Centrifugal Filter 
(Millipore) with a cutoff molecular weight of 10,000 Da and the 
rTM456-PEG5000-OMe was concentrated. The total amount of pure 
rTM456-PEG5000-OMe was measured by Bradford assay.
2.5. Incorporation of azide functionality to the C-terminal of rTM456-
LPETG and its covalent PEGylation via copper-free click chemistry (CFCC)
rTM456-LPETG (14 μM) was mixed with SrtA (2 μM) and NH2-Gly-
Gly-PEG3-azide (3 mM) in reaction buffer (20 mM Tris and 150 mM 
NaCl, pH 8.0) to first prepare the product of rTM-PEG3-azide. The 
rTM456-LPETG-PEG3-azide was purified from the remaining reaction 
mixture by collecting the pass-through fraction of His SpinTrap column 
(GE Healthcare), and dialyzed by Amicon Ultra Centrifugal Filter 
(Millipore) with a cutoff molecular weight of 10,000 Da to obtain the 
pure product. Then, the pure rTM456-LPETG-PEG3-azide (8 μM) and 
DBCO-PEG5000-OMe (64 μM) were incubated and shaken at room 
temperature overnight in reaction buffer (20 mM Tris and 150 mM 
NaCl, pH 8.0). The excess unreacted DBCO-PEG5000 was removed by 
dialyzing via Amicon Ultra Centrifugal Filter (Millipore) with a cutoff 
molecular weight of 10,000 Da. The successful formation of rTM456-
PEG3-PEG5000-OMe was measured and stored in −20 °C until use.
2.6. SDS-PAGE Coomassie blue staining and Western blot analysis
The rTM456-LPETG, SrtA, rTM456-PEG5000-OMe and rTM456-PEG3-
PEG5000-OMe were detected in 15% SDS-polyacrylamide gels under 
reducing conditions by Coomassie Blue staining. Also, Western blot was 
conducted by transferring the gel onto polyvinylidene difluoride 
membranes by Trans-Blot Turbo Transfer system (Bio-Rad). The mem-
branes were blocked in 5% non-fat milk in TBST (contained 0.05% of 
Tween 20) for anti-TM and in 10% BSA in TBST for anti-PEG at room 
temperature for 1 h with gentle shaking. Primary anti-TM monoclonal 
antibody (1:2000) or anti-PEG monoclonal antibody (1:1000) in 5%
non-fat milk or in 10% BSA was incubated with the membrane at 4 °C 
overnight. The membranes were then washed with TBST (3 × 10 min)
3. Results and discussion
Translational incorporation of functional amino acids has been a
very promising strategy to improve protein physicochemical and bio-
logical properties and create functional groups for site-specific protein
modification applications (Boutureira and Bernardes, 2015;
Hendrickson et al., 2004). Azidohomolananine can serve as a methio-
nine surrogate and can be incorporated into proteins, providing an
azidohomolananine-containing protein for chemo-selective modifica-
tion (Kiick et al., 2002). In our preliminary studies, we have expressed
recombinant TM456 construct containing an azido-functionalized me-
thionine analog at the C-terminus for site-specific immobilization (Sun
et al., 2006) and modification (Zhang et al., 2013) via bio-orthogonal
chemistry. However, low translational efficiency of the unnatural
amino acid azidohomolananine is the limiting factor for larger scale
preparation, modification and functional study of the protein. Enzy-
matic modification provides another robust tool for site-specific protein
modification (Sunbul and Yin, 2009). In our preliminary study, we
expressed recombinant TM456 containing a LPETG pentapeptide at the
C-terminus (rTM456-LPETG) for enzymatic end-point immobilization
(Jiang et al., 2012) and modification (Jiang et al., 2014) via SML.
Therefore, we speculated that rTM456-LPETG is versatile for site-specific
PEGylation of rTM456 directly with glycine chain-end functionalized
PEG via SML. In this study, the rTM456-LPETG was prepared by ex-
pression in E. coli B834 (DE3) cells with TM456GGMLPETG and all tags
plasmid. After purification, the protein integrity was confirmed by SDS-
PAGE (Fig. 3A). Optimization for the large-scale expression and effi-
cient purification was conducted to provide sufficient amount of
rTM456-LPETG for its PEG conjugate preparation and stability and ac-
tivity studies. In addition, an azide functionality was easily in-
corporated to rTM456-LPETG with a glycine molecule containing azide
via SML, which facilitates a site-specific PEGylation via CFCC.
3.1. C-terminal covalent PEGylation of rTM456-LPETG via SML
It has been known that a diglycine at the N-terminus of a nucleo-
phile shows the highest yield for Sortase-catalyzed transpeptidation and
the addition of any more glycines has no significant effect on the re-
action rate (Tsukiji and Nagamune, 2009). Therefore, diglycine was
chosen as the nucleophile of the PEG molecule in our study. Specifi-
cally, N-terminal diglycine-containing PEG5000-OMe (NH2-Gly-Gly-NH-
PEG5000-OMe) was used for site-specific PEGylation of rTM456-LPETG
via SML. In this study, the His-tag at the C-terminus of rTM456-LPETG
and SrtA allows for an easy removal of the unreacted rTM456-LPETG-
His-tag and SrtA-His-tag by a nickel affinity column, while the PEGy-
lated product was obtained directly by passing the reaction mixture
through the nickel column as it does not have the His-tag due to the
cleavage of T/G in LPETG motif after the SML reaction (Fig. 2). Briefly,
rTM456-LPETG was incubated with SrtA and NH2-Gly-Gly-NH-PEG5000-
OMe in reaction buffer for 3 h at 37 °C followed by passing through the
nickel affinity column to afford the C-terminal PEGylated rTM456-
LPETG (rTM456-PEG5000-OMe). The resultant rTM456-PEG5000-OMe was
analyzed by SDS-PAGE and Western blot (Fig. 3). As shown in the SDS-
PAGE gel resulting from Coomassie blue staining (Fig. 3A), a major
band with larger molecular weight formed, indicating the successful
PEGylation via SML. Also, Western blot with mouse monoclonal
antibody specific to human TM (Fig. 3B) and rabbit monoclonal anti-
body specific to PEG molecule (Fig. 3C) confirmed the PEGylated
rTM456-LPETG conjugates. From the Western blot analysis with anti-TM
antibody, two extra bands with much higher molecular weight were
observed for the SML reaction products (Fig. 3B). The top band might
be the dimer of the rTM456 formed during the reaction or purification
step. Another one might be the rTM456-LPETG-acyl-SrtA intermediate
that stays unreacted with the Gly2-PEG5000-OMe nucleophile. This in-
dicates that the larger substrate may have steric issue that prevents it
reaching and reacting with the acyl-SrtA intermediate, which is in
agreement with our previous finding (Jiang et al., 2014). This might be
the drawback of SML with larger molecules in conjugation.
3.2. C-terminal covalent PEGylation of rTM456-LPETG via CFCC
Next, we investigated an alternative PEGylation of rTM456 con-
taining an azide at the C-terminus with DBCO-PEG5000-OMe via CFCC,
which is very efficient in protein modification (Jang et al., 2012). First,
an azide functionality was incorporated into rTM456-LPETG with di-
glycine-PEG3-azide via SML by an efficient purification flow as shown in
Fig. 2. Then, the pure rTM456-PEG3-azide was incubated with DBCO-
PEG5000-OMe in the same reaction buffer for 12 h at room temperature.
The PEGylated rTM456 product was confirmed by SDS-PAGE from
Coomassie blue staining (Fig. 3A) and Western blot with both anti-TM
(Fig. 3B) and anti-PEG antibodies (Fig. 3C). These results demonstrate
that CFCC-mediated PEGylation provides a site-specific protein mod-
ification. There is an extra band around 16 kDa observed from the
CFCC-mediated PEGylation on SDS-PAGE. This may be the degraded
fragment from rTM456 as it is unstable during 12 h long time of reac-
tion. This extra band was not confirmed in the Western blot (Supporting
Information, S1). This may be due to that the anti-TM antibody does not
recognize this small fragment. Therefore, we conducted the reaction for
3 h at room temperature. As a result, there was no this extra band
formed in addition to the PEGylated product (Supporting Information,
S2). In addition, the unreacted rTM456 was observed in SDS-PAGE but
not in Western blot because that only one sixth amounts of the proteins
were used in Western blot. However, it was observed when larger
amount of the protein was used (Supporting Information, S3).
3.3. Stability of PEGylated rTM456-LPETG conjugates under proteolytic
digestion by trypsin
As described above, PEGylation could enhance the protein's stabi-
lity. In this study, a Trypsin digestion assay was conducted to evaluate
the PEGylation effect on the stability of rTM456-LPETG, which is often
used to test the resistance to proteolytic degradation (Guan et al., 2004;
Veronese et al., 1996). Briefly, rTM456-LPETG, rTM456-PEG5000-OMe or
rTM456-PEG3-PEG5000-OMe was incubated with Trypsin in the reaction
buffer at 37 °C for 0, 1, 2, 3, 4, 5 and 6 h, respectively. Then, all samples
were electrophoresed on a SDS-PAGE gel and the undigested protein
were determined by Western blot. As a result, unmodified rTM456-
LPETG was completely digested at 4 h, while rTM456-PEG5000-OMe and
rTM456-PEG3-PEG5000-OMe were almost unchanged until 6 h after
Trypsin treatment (Figs. 4B and 5A). Interestingly, both PEGylated
rTM456-LPETG conjugates showed an immediate breakdown at 0 h upon
Trypsin treatment, which cleaved a small part from the N-terminal as
Fig. 2. Site-Specific PEGylation via SML and rapid purification flowchart of SML product via Nickel affinity column.
confirmed by Western blot with both anti-TM antibody and anti-PEG
antibody. Both SML-mediated and CCFC-mediated PEGylation products
showed the same trend of protein stability against Trypsin digestion as
shown in Western blot with both anti-TM antibody (Fig. 4B) and anti-
PEG antibody (Fig. 5). rTM456-LPETG, rTM456-PEG5000-OMe and
rTM456-PEG3-PEG5000-OMe were stable in the reaction buffer (Fig. 4A).
All these results indicate that PEGylation of rTM456-LPETG enhanced
protein stability.
3.4. Protein C activation activity assay of PEGylated rTM456-LPETG
conjugates with or without trypsin digestion
In order to know whether PEGylation of rTM456 affects rTM456's
anticoagulant activity, protein C activation activities of rTM456-LPETG,
rTM456-PEG5000-OMe and rTM456-PEG3-PEG5000-OMe were measured.
Briefly, rTM456-LPETG, rTM456-PEG5000-OMe or rTM456-PEG3-PEG5000-
OMe was first incubated with thrombin and protein C to generate ac-
tivated protein C (APC). Then, APC was measured by quantifying the
hydrolysis product of the chromogenic substrate at 405 nm. As shown
in Fig. 6A, rTM-PEG5000-OMe and rTM-PEG3-PEG5000-OMe conjugates
showed a similar level of protein C activation activity to rTM456-LPETG,
indicating that the PEGylation didn't hamper the rTM456-LPETG ac-
tivity. These results demonstrate that the site specific PEGylation of
rTM456 did not affect its anticoagulant activity, even using a two-step
reaction involving SML and CFCC. In addition, protein C activation
capability was monitored for all Trypsin digestion sample solutions as
described above. As a result, unmodified rTM456-LPETG lost 50% pro-
tein C activation activity upon 4 h Trypsin digestion (Fig. 6B), while
PEGylated rTM456-LPETG, rTM456-PEG5000-OMe and rTM456-PEG3-
PEG5000-OMe maintained protein C activation activity after 6 h Trypsin
treatment (Fig. 6C and D), which are well agreement with the Western
blot results above (Figs. 4 and 5). These results further confirm the
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without Trypsin, (B) rTM456-LPETG, rTM-PEG5000-OMe and rTM456-PEG3-PEG5000-OMe with Trypsin examined by Western blot with mouse monoclonal anti-TM
antibody. Gel intensities are normalized to 0 h time of Trypsin digestion.
enhanced stability of rTM456 through PEGylation.
3.5. Thrombin clotting time (TCT) assay of PEGylated rTM456-LPETG
conjugates
The thrombin clotting time (TCT) was measured for rTM456-LPETG,
rTM456-PEG5000-OMe and rTM456-PEG3-PEG5000-OMe, respectively, in
order to determine the effect of PEGylation on their anticoagulation
activity. Different concentrations of rTM456-LPETG, rTM456-PEG5000-
OMe and rTM456-PEG3-PEG5000-OMe were mixed with human plasma,
and then human thrombin was added to trigger the clotting. rTM456-
LPETG, rTM456-PEG5000-OMe and rTM456-PEG3-PEG5000-OMe showed a
concentration-dependent clotting time prolongation, while the control
PEG molecules did not show any activity (Fig. 7). There was a clear
difference in clotting time for rTM456-LPETG and PEGylated rTM456-
LPETG conjugates. At higher concentrations, PEGylated rTM456-LPETG
conjugates showed a longer TCT compared to unmodified rTM456-
LPETG. This result is different from the in vitro protein C activation
assay above, in which rTM456-LPETG and PEGylated rTM456-LPETG
conjugates showed the same level of APC generation activity. This can
be explained that the TCT assay was conducted in human plasma, in
which un-modified rTM456-LPETG may be unstable due to enzymatic
degradation. However, PEGylated rTM456-LPETG may be resistant to
the enzymatic degradation. This result indicates possible in vivo stabi-
lity of the PEGylated rTM456-LPETG conjugates, which is expected in a
future animal study.
4. Conclusions
Protein modification warrants improved biological activity and
pharmacokinetic properties. Two successful site-specific strategies for
PEGylation of rTM456 were demonstrated via Sortase A-mediated liga-
tion (SML) and copper-free click chemistry (CFCC). The PEGylation by
both chemistries did not upset the rTM456 biological activities, such as
protein C activation activity and anti-thrombin activity. Both reactions
have advantages of mild reaction conditions and high yields. In
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addition, the His-tag of both rTM456 and Sortase A allows for a quick
purification of the PEGylated product via a nickel affinity column. We
anticipate that the PEGylated rTM456 will show an enhanced pharma-
cokinetic property in vivo. These strategies are viable for modification of
a variety of proteins with different molecules for elevated activity and
stability, novel functions, and other specific properties of interest as
well.
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